WallStreetZenWallStreetZen

NASDAQ: INCY
Incyte Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for INCY

Based on 14 analysts offering 12 month price targets for Incyte Corp

Min Forecast
$60.00-41.47%
Avg Forecast
$96.14-6.22%
Max Forecast
$125.00+21.93%

Should I buy or sell INCY stock?

Based on 14 analysts offering ratings for Incyte Corp.

Strong Buy
Strong Buy
9 analysts 64.29%
Buy
0 analysts 0%
Hold
4 analysts 28.57%
Sell
1 analysts 7.14%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their INCY stock forecasts and price targets.

INCY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-24Find Out Why
lockedlocked$00.00+00.00%2025-11-04Find Out Why
lockedlocked$00.00+00.00%2025-11-03
lockedlocked$00.00+00.00%2025-10-29
lockedlocked$00.00+00.00%2025-10-29
Wells Fargo
Top 2%
99
Strong BuyMaintains$97.00-5.38%2025-10-29Find out why
Barclays
Bottom 6%
6
Strong BuyMaintains$101.00-1.48%2025-10-29
JP Morgan
Top 4%
97
HoldMaintains$89.00-13.19%2025-10-09
Stifel Nicolaus
Top 21%
80
Strong BuyMaintains$115.00+12.17%2025-09-22
Bank of America
Top 19%
82
Strong BuyMaintains$104.00+1.44%2025-09-04

1 of 2

Forecast return on equity

Is INCY forecast to generate an efficient return?

Company
43.11%
Industry
259.27%
Market
228.52%
INCY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INCY forecast to generate an efficient return on assets?

Company
31.67%
Industry
90.14%
INCY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INCY earnings per share forecast

What is INCY's earnings per share in the next 3 years based on estimates from 30 analysts?

Avg 1 year Forecast
$6.98+15.55%
Avg 2 year Forecast
$8.06+33.42%
Avg 3 year Forecast
$9.18+51.94%
INCY's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

INCY revenue forecast

What is INCY's revenue in the next 3 years based on estimates from 28 analysts?

Avg 1 year Forecast
$5.1B+5.38%
Avg 2 year Forecast
$5.6B+16.85%
Avg 3 year Forecast
$6.2B+28.09%
INCY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

INCY earnings growth forecast

How is INCY forecast to perform vs Biotechnology companies and vs the US market?

Company
14.93%
Industry
44.75%
Market
42.88%
INCY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
INCY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
INCY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

INCY revenue growth forecast

How is INCY forecast to perform vs Biotechnology companies and vs the US market?

Company
8.61%
Industry
102.02%
Market
25.67%
INCY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
INCY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

INCY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INCY$102.52$96.14-6.22%Strong Buy
GMAB$31.74$43.75+37.84%Strong Buy
UTHR$489.31$495.08+1.18%Buy
RPRX$39.73$46.00+15.78%Strong Buy
BNTX$96.25$132.00+37.14%Buy
View Top Biotech Stocks

Incyte Stock Forecast FAQ

Is Incyte Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 14 Wall Street analysts covering (NASDAQ: INCY) stock is to Strong Buy INCY stock.

Out of 14 analysts, 9 (64.29%) are recommending INCY as a Strong Buy, 0 (0%) are recommending INCY as a Buy, 4 (28.57%) are recommending INCY as a Hold, 1 (7.14%) are recommending INCY as a Sell, and 0 (0%) are recommending INCY as a Strong Sell.

If you're new to stock investing, here's how to buy Incyte stock.

What is INCY's earnings growth forecast for 2025-2027?

(NASDAQ: INCY) Incyte's forecast annual earnings growth rate of 14.93% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.

Incyte's earnings in 2025 is $1,188,583,000.On average, 30 Wall Street analysts forecast INCY's earnings for 2025 to be $1,370,136,144, with the lowest INCY earnings forecast at $1,256,740,151, and the highest INCY earnings forecast at $1,475,954,081. On average, 29 Wall Street analysts forecast INCY's earnings for 2026 to be $1,582,125,399, with the lowest INCY earnings forecast at $1,216,513,629, and the highest INCY earnings forecast at $1,923,275,360.

In 2027, INCY is forecast to generate $1,801,692,710 in earnings, with the lowest earnings forecast at $709,942,159 and the highest earnings forecast at $2,376,780,804.

What is INCY's revenue growth forecast for 2025-2027?

(NASDAQ: INCY) Incyte's forecast annual revenue growth rate of 8.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.

Incyte's revenue in 2025 is $4,813,105,000.On average, 28 Wall Street analysts forecast INCY's revenue for 2025 to be $995,748,749,616, with the lowest INCY revenue forecast at $947,257,041,975, and the highest INCY revenue forecast at $1,043,455,166,445. On average, 28 Wall Street analysts forecast INCY's revenue for 2026 to be $1,104,118,881,672, with the lowest INCY revenue forecast at $986,717,905,278, and the highest INCY revenue forecast at $1,208,169,914,262.

In 2027, INCY is forecast to generate $1,210,329,463,995 in revenue, with the lowest revenue forecast at $1,062,694,791,339 and the highest revenue forecast at $1,443,757,157,862.

What is INCY's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: INCY) forecast ROA is 31.67%, which is lower than the forecast US Biotechnology industry average of 90.14%.

What is INCY's Price Target?

According to 14 Wall Street analysts that have issued a 1 year INCY price target, the average INCY price target is $96.14, with the highest INCY stock price forecast at $125.00 and the lowest INCY stock price forecast at $60.00.

On average, Wall Street analysts predict that Incyte's share price could fall to $96.14 by Nov 24, 2026. The average Incyte stock price prediction forecasts a potential downside of 6.22% from the current INCY share price of $102.52.

What is INCY's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: INCY) Incyte's current Earnings Per Share (EPS) is $6.04. On average, analysts forecast that INCY's EPS will be $6.98 for 2025, with the lowest EPS forecast at $6.40, and the highest EPS forecast at $7.52. On average, analysts forecast that INCY's EPS will be $8.06 for 2026, with the lowest EPS forecast at $6.20, and the highest EPS forecast at $9.80. In 2027, INCY's EPS is forecast to hit $9.18 (min: $3.62, max: $12.11).

What is INCY's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: INCY) forecast ROE is 43.11%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.